SPIN1 and renal cell carcinoma: Findings of OCR inhibition in RCC cells with telaglenastat and cabozantinib were similar to those of telaglenastat plus everolimus, with the combination exhibiting a greater decrease in OCR than either agent alone (Fig 4C).